IUHSA
NTLA icon

Itau Unibanco Holding S.A.’s Intellia Therapeutics NTLA Stock Holding History

Itau Unibanco Holding S.A.’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-53
Closed -$377 – 429
2025
Q2 		$377 Buy
+53
New +$435 ﹤0.01% 379
2024
Q3 		– Sell
-839
Closed -$18.8K – 399
2024
Q2 		$18.8K Buy
+839
New +$20K ﹤0.01% 222
2024
Q1 		– Sell
-3,207
Closed -$97.8K – 284
2023
Q4 		$97.8K Buy
3,207
+95
+3% +$2.73K ﹤0.01% 178
2023
Q3 		$98.4K Buy
3,112
+169
+6% +$6.56K ﹤0.01% 202
2023
Q2 		$120K Buy
2,943
+453
+18% +$18.4K 0.01% 217
2023
Q1 		$92.8K Sell
2,490
-20
-0.8% -$784 ﹤0.01% 250
2022
Q4 		$88.6K Buy
2,510
+1,189
+90% +$56.5K ﹤0.01% 309
2022
Q3 		$74K Sell
1,321
-508
-28% -$31.5K ﹤0.01% 359
2022
Q2 		$95K Buy
1,829
+768
+72% +$39K ﹤0.01% 295
2022
Q1 		$77K Buy
1,061
+16
+2% +$1.36K ﹤0.01% 280
2021
Q4 		$127K Buy
1,045
+749
+253% +$93.8K ﹤0.01% 209
2021
Q3 		$40K Buy
296
+8
+3% +$1.21K ﹤0.01% 287
2021
Q2 		$47K Buy
+288
New +$22.4K ﹤0.01% 178

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Itau Unibanco Holding S.A.'s NTLA Position: Q3 2025 in Review

Itau Unibanco Holding S.A. sold out of Intellia Therapeutics (NTLA) in Q3 2025, closing a stake of 53 shares — an estimated $377 sold.

Itau Unibanco Holding S.A. first reported a position in NTLA in Q2 2021 and held it in 13 quarters. The position peaked at $127K in Q4 2021. 282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • Itau Unibanco Holding S.A. reported no remaining Intellia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Itau Unibanco Holding S.A. sold 53 Intellia Therapeutics shares in Q3 2025, an estimated $377.
  • Itau Unibanco Holding S.A. first reported a position in Intellia Therapeutics in Q2 2021 and held it in 13 quarters.
  • Itau Unibanco Holding S.A.'s Intellia Therapeutics position peaked at $127K in Q4 2021.
  • 282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on Itau Unibanco Holding S.A.'s 13F filing for Q3 2025, filed 12 Nov 2025.